Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
复制标题
DOI：
10.1016/s0140-6736(22)00327-0
复制
发表时间：
2022-04-23
期刊：
影响因子：
--
通讯作者：
Spector TD
中科院分区：
文献类型：
--
作者：
Menni C;Valdes AM;Polidori L;Antonelli M;Penamakuri S;Nogal A;Louca P;May A;Figueiredo JC;Hu C;Molteni E;Canas L;Österdahl MF;Modat M;Sudre CH;Fox B;Hammers A;Wolf J;Capdevila J;Chan AT;David SP;Steves CJ;Ourselin S;Spector TD
令人关注的SARS-CoV-2变种“omicron”似乎没有“delta”那么严重。我们的目标是量化接种人群在症状患病率、住院风险和症状持续时间方面的差异。在这项前瞻性纵向观察研究中，我们收集了在ZOE COVID应用程序（以前称为COVID症状研究应用程序）中自我报告测试结果和症状的参与者的数据。符合条件的参与者年龄在16-99岁之间，居住在英国，体重指数在15至55 kg/m2之间，接受过至少两剂任何SARS-CoV-2疫苗，有症状，并且在研究期间记录了SARS-CoV-2症状性PCR或侧流阳性结果。主要结果是在组粒流行期间感染的参与者与在三角洲流行期间感染的参与者相比，在阳性检测前后7天内出现给定症状（在应用程序中监测的32人中）或住院的可能性。在2021年6月1日至2022年1月17日期间，我们确定了63 002名SARS-CoV-2检测呈阳性并在ZOE应用程序中报告症状的参与者。这些患者在年龄、性别和疫苗剂量方面按1:1匹配，分为两个时间段（2021年6月1日至11月27日，δ型流行率为>70%,n=4990； 2021年12月20日至2022年1月17日，组粒流行率为>70%,n=4990）。在组微粒流行期间感染的受试者嗅觉丧失的发生率低于δ流行期间感染的受试者（16.7% vs 52.7%，优势比[OR] 0.17; 95% CI 0.16 - 0.19, p< 0.001）。组粒流行期间喉咙痛比δ型流行期间更常见（70.5% vs 60.8%, 1.55; 1.43 - 1.69, p< 0.001）。组粒流行期间的住院率低于δ流行期间（1.9% vs 2.6%, OR 0.75; 95% CI 0.57 ~ 0.98, p= 0.03）。以组粒感染为特征的症状的流行程度与δ型SARS-CoV-2变体的症状不同，显然对下呼吸道的影响较小，住院的可能性也较低。我们的数据表明，患病时间较短，具有潜在传染性，这应该会影响工作卫生政策和公共卫生建议。惠康信托，ZOE，国家卫生研究所，慢性病研究基金会，国家卫生研究院，医学研究委员会
The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population. In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16–99 years, based in the UK, with a body-mass index between 15 and 55 kg/m2, had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence. Between June 1, 2021, and Jan 17, 2022, we identified 63 002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to Nov 27, 2021, delta prevalent at >70%; n=4990, and Dec 20, 2021, to Jan 17, 2022, omicron prevalent at >70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16–0·19, p<0·001). Sore throat was more common during omicron prevalence than during delta prevalence (70·5% vs 60·8%, 1·55; 1·43–1·69, p<0·001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1·9% vs 2·6%, OR 0·75; 95% CI 0·57–0·98, p=0·03). The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. Our data indicate a shorter period of illness and potentially of infectiousness which should impact work–health policies and public health advice. Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council
影响因子：
10
作者：
Bowyer RCE;Varsavsky T;Thompson EJ;Sudre CH;Murray BAK;Freidin MB;Yarand D;Ganesh S;Capdevila J;Bakker E;Cardoso MJ;Davies R;Wolf J;Spector TD;Ourselin S;Steves CJ;Menni C
通讯作者：
Menni C